KLA Results Top Wall Street Forecasts, Yet Stock Falls on High Expectations
AI-driven demand lifts KLA to $3.66B Q4 revenue and $1.05 EPS beat.
Already have an account? Sign in.
AI-driven demand lifts KLA to $3.66B Q4 revenue and $1.05 EPS beat.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.